Welcome to Insider Healthcare. I’m Lydia Ramsey Pflanzer, and today in healthcare news:
- Two top neuroscience experts resigned from an FDA panel after the agency approved a new Alzheimer’s drug;
- Amazon and Walmart’s latest battleground is cheap prescriptions;
- Transcarent, a startup backed by Livongo veterans, just raised $58 million at a nearly $500 million valuation.
Two doctors have resigned from a prestigious panel after FDA approved a controversial Alzheimer’s drug
- Two top neuroscience experts resigned this week from a committee that advises the FDA.
- The doctors stepped down after the agency approved a controversial Alzheimer’s drug called Aduhelm.
- Their committee voted in November that the FDA shouldn’t approve the drug.
Amazon and Walmart are competing to offer you the cheapest prescriptions, and it could shake up the entire pharmacy industry
- Amazon and Walmart are competing to drive down drug costs, challenging traditional pharmacies.
- Prime members get some for $1 a month. Walmart offers some at no cost, says a Morgan Stanley note.
- It’s not the first time the two have faced off: They’re also competing on virtual and primary care.
A startup backed by Livongo veterans just got a nearly $500 million valuation, and it’s coming for healthcare’s middlemen
- Healthcare startup Transcarent just raised $58 million from investors including General Catalyst.
- The round valued the two-year-old Transcarent at nearly $500 million, Insider has learned.
- It’s aiming to route patients to the care they need without networks and navigators.
More stories we’re reading:
- The Biden administration is set to buy 500 million Pfizer vaccine doses to ship around the world, according to reports (Insider)
- Dr. Scott Gottlieb: the Delta variant is likely not going to be a threat to the US until the fall (CNBC)
- ‘I was pregnant and then I wasn’t.’ How a miscarriage led a startup employee to build a company that’s now funded by Alexis Ohanian’s Seven Seven Six. (Insider)
- Nursing homes are struggling to hire workers (Axios)